Bone Biologics Corporation (BBLGW)

34.72 -2.28 (-6.16%) 收市：04:00PM EDT

Bone Biologics Corporation

2 Burlington Woods Drive
Suite 100
Burlington, MA 01803
United States
781 552 4452
https://www.bonebiologics.com

版塊: Healthcare
行業: Medical Devices
全職員工: 2

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Jeffrey Frelick	CEO & President	325k	無	1966
Ms. Deina H. Walsh	Chief Financial Officer	212.5k	無	1964
Dr. Shun'ichi Kuroda	Co-Founder & Member of Scientific Advisory Board	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

公司管治

截至 無 止，Bone Biologics Corporation 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。